Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial

Brian G. Feagan, Bruce E. Sands, William J. Sandborn, +54

˜The œLancet. Gastroenterology & hepatology

Systemic TreatmentGolimumab MonotherapyGastroenterologyPathologyUlcerative Colitis +2

Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn’s disease: report of the OPERA study

William J. Sandborn, Scott D. Lee, Dino Tarabar, +17

Gut

Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial

Laurent Peyrin‐Biroulet, Ailsa Hart, Peter Bossuyt, +323

˜The œLancet. Gastroenterology & hepatology

InflammationAnti-inflammatoryImmunologyGastroenterologyMaintenance Therapy +5

Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study

Laurent Peyrin‐Biroulet, Jessica R. Allegretti, David T. Rubin, +154

Gastroenterology

Small intestinal bacterial overgrowth mimicking acute flare as a pitfall in patients with Crohn's Disease

Jochen Klaus, Ulrike Spaniol, Guido Adler, +3

BMC Gastroenterology

Effect of systemic glucocorticoid therapy on bone metabolism and the osteoprotegerin system in patients with active Crohn's disease

Christian von Tirpitz, Sonja Epp, Jochen Klaus, +7

European Journal of Gastroenterology & Hepatology

A Randomised, Double-blind, Placebo-controlled Trial of<i>Trichuris suis</i>ova in Active Crohn’s disease

Jürgen Schölmerich, Klaus Fellermann, Frank Seibold, +15

Journal of Crohn s and Colitis

Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies

David T. Rubin, Jessica R. Allegretti, Julián Panés, +331

The Lancet

Placebo-controlled InductionGastroenterologyPathologyClinical GastroenterologyGastrointestinal Pathology +4

Increase of bone mineral density with sodium fluoride in patients with Crohnʼs disease

Christian von Tirpitz, Jochen Klaus, Joachim Brückel, +5

European Journal of Gastroenterology & Hepatology

NOD2 Polymorphism Predicts Response to Treatment in Crohn’s Disease—First Steps to a Personalized Therapy

Jan Hendrik Niess, Jochen Klaus, Johannes Stephani, +6

Digestive Diseases and Sciences